Spero Therapeutics SPRO 深 沪
等待开盘 07-07 09:30:00 美东时间
2.19
-0.010
-0.45%
华盛通- 最 高2.20
- 今 开2.17
- 成交量 35.05万股
- 最 低 2.15
- 昨 收 2.20
- 总市值 1.27亿
- 52周最高 3.08
- 市盈率 静 15.08
- 换手率 0.61%
- 52周最低 1.80
- 委 比 -63.64%
- 总股本 5790.15万
- 历史最高 23.639
- 量 比 0.42
- 振 幅 2.27%
- 历史最低 0.5052
- 每 手 1
- 风险率 0.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Smith & Wesson Brands Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Shares of Smith & Wesson Brands Inc (NASDAQ:SWBI) rose sharply in pre-market trading as the company posted better-than-expected fourth-quarter results after Wednesday’s closing bell. Smith & Wesson reported quarterly earnings of 36 cents per share, which beat the analyst estimate of 23 cents. Quarte...
06-18 18:10
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs
GSK plc (NYSE:GSK) and Spero Therapeutics, Inc. (NASDAQ:SPRO) announced on Wednesday that the U.S. Food and Drug Administration has approved Utebzi (tebipenem pivoxil hydrobromide), an oral antibiotic for adults with complicated urinary tract infections (cUTIs). First Oral Carbapenem Approved For Th...
06-18 01:29
Spero Therapeutics Q1 EPS $(0.13) Beats $(0.18) Estimate, Sales $258.000K Down From $5.874M YoY
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 48 percent increase over losses of $(0.25) per share from
05-14 05:15
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
Spero Therapeutics Q4 EPS $0.53 Beats $(0.40) Estimate, Sales $41.297M Up From $15.044M YoY
Spero Therapeutics (NASDAQ:SPRO) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $(0.40) by 232.5 percent. This is a 239.47 percent increase over losses of $(0.38) per share
03-27 04:06
Earnings Scheduled For March 26, 2026
Companies Reporting Before The Bell • ProShares UltraShort Russell2000 (NYSE:TW...
03-26 19:11
GSK Resubmits NDA, Triggering Milestone for Spero Therapeutics
Spero Therapeutics ( ($SPRO) ) has provided an update. On December 19, 2025, Sp...
2025-12-19 21:48
Spero Therapeutics Announces GSK Files New Drug Application Resubmission to FDA For Tebipenem HBr To Treat Complicated Urinary Tract Infections
Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today
2025-12-19 21:13
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
On November 3, 2025, Spero Therapeutics granted 90,000 RSUs to a new employee under its 2019 Inducement Plan. The RSUs vest over four years, starting December 1, 2025, contingent on continued employment. This grant aligns with Nasdaq Listing Rule 5635(c)(4) to attract new hires.
2025-11-28 13:00
Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update
<p>Spero Therapeutics announced positive results from the Phase 3 PIVOT-PO trial of tebipenem HBr for complicated urinary tract infections (cUTI), showing non-inferiority to intravenous imipenem-cilastatin. The company expects GSK to submit FDA filing by Q4 2025, with a regulatory decision anticipated in 2H 2026. Spero reported a net loss of $7.4 million for Q3 2025, with cash reserves of $48.6 million expected to fund operations into 2028. The S...
2025-11-13 21:05
